Jun 2026 (Q2 FY26) — Aug 13, 2026
Elutia Inc. Q2 FY26 — Strategic Divestitures and NXT 41X Commercialization Focus
Read the full callElutia (ELUT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Elutia earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2.4 | −11.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -327.9 | −23.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.82 +3.80% · +$0.03
Performance −7.9% 1Y
1Y: $0.89 on 17 Oct 2025 → $0.82. High $1.22 (3 Mar 2026), low $0.51 (17 Dec 2025).
- Previous close
- $0.79
- 52-week range
- $0.51 – $1.22
- One year
- −8.89%
Overview
- Symbol
- ELUT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Elutia earnings calls (ELUT)
Financials
What the filings say
Net profit, year on year: +20% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 5 | 3 | 3 | 3 | 3 | 3 | 2 |
| Operating profit | -9 | -8 | -7 | -8 | -5 | -7 | -6 | -8 |
| Operating margin | −250.6% | −154.2% | −229.7% | −304.5% | −156.7% | −200.5% | −203.8% | −327.9% |
| Interest | 0 | — | 1 | 1 | 0 | — | — | — |
| Profit before tax | 3 | -9 | -2 | -7 | -0 | -7 | -8 | -8 |
| Tax rate | 0.2% | −0.0% | −0.4% | −0.1% | −2.1% | 0.2% | −0.9% | −0.1% |
| Net profit | 1 | -9 | -4 | -10 | -4 | 71 | -7 | -8 |
| EPS ($ per share) | 0.03 | — | -0.10 | -0.23 | -0.09 | — | -0.17 | -0.17 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | — | — | — | — | — | — |
| Reserves | -57 | -80 | -105 | -138 | -176 | -230 | -176 |
| Total liabilities | 55 | 62 | 54 | 74 | 82 | 82 | 35 |
| Fixed assets | 1 | 1 | 1 | 0 | 0 | 1 | 3 |
| Total assets | 45 | 83 | 67 | 69 | 43 | 36 | 62 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -7 | -14 | -15 | -21 | -22 | -23 | -45 |
| Cash from investing | -1 | -1 | -0 | -1 | 14 | -0 | 79 |
| Cash from financing | 8 | 51 | 7 | 9 | 10 | 17 | -11 |
| Capital expenditure | -1 | -1 | -0 | -1 | -0 | -1 | -2 |
| Free cash flow | -8 | -14 | -16 | -22 | -22 | -23 | -47 |
Insider filings
47 filings between Nov 13, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
$236.7K
16 purchases by 6 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 15
- Option exercise — converted options into shares
- 13
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 other filings, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| RAKIN KEVIN | $100.2K | — | Jan 30, 2026 |
| NEELS GUIDO J | $52.6K | — | Jan 30, 2026 |
| Ferguson Matthew | $38.4K | — | Dec 17, 2025 |
| Colpman David | $17.8K | — | Dec 17, 2025 |
| Mills C Randal | $14.6K | — | Dec 17, 2025 |
| Makes Brigid | $13.0K | — | Dec 17, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Mills C Randal PRESIDENT AND CEO | Tax withheld | 9,718 | $7.8K |
| Sep 10, 2026 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Option exercise | 12,500 | — |
| Sep 10, 2026 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Tax withheld | 4,269 | $3.4K |
| Sep 10, 2026 | Mills C Randal PRESIDENT AND CEO | Option exercise | 27,083 | — |
| Sep 10, 2026 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Tax withheld | 4,486 | $3.6K |
| Sep 10, 2026 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Option exercise | 12,500 | — |
| Jun 21, 2026 | Mills C Randal PRESIDENT AND CEO | Tax withheld | 8,064 | $8.5K |
| Jun 21, 2026 | Mills C Randal PRESIDENT AND CEO | Option exercise | 22,473 | — |
| Jun 10, 2026 | Mills C Randal PRESIDENT AND CEO | Tax withheld | 9,718 | $10.1K |
| Jun 10, 2026 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Option exercise | 12,500 | — |
| Jun 10, 2026 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Tax withheld | 4,269 | $4.4K |
| Jun 10, 2026 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Option exercise | 12,500 | — |
| Jun 10, 2026 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Tax withheld | 4,485 | $4.7K |
| Jun 10, 2026 | Mills C Randal PRESIDENT AND CEO | Option exercise | 27,083 | — |
| Jun 1, 2026 | RAKIN KEVIN Director | Gift | 70,000 | $0 |
| Jun 1, 2026 | RAKIN KEVIN Director | Other | 50,000 | $0 |
| Mar 10, 2026 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Tax withheld | 4,613 | $5.0K |
| Mar 10, 2026 | Mills C Randal PRESIDENT AND CEO | Tax withheld | 11,100 | $12.1K |
| Mar 10, 2026 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Option exercise | 12,500 | — |
| Mar 10, 2026 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Option exercise | 12,500 | — |
| Mar 10, 2026 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Tax withheld | 5,123 | $5.6K |
| Mar 10, 2026 | Mills C Randal PRESIDENT AND CEO | Option exercise | 27,084 | — |
| Jan 30, 2026 | RAKIN KEVIN Director | Purchase | 70,000 | $74.2K |
| Jan 30, 2026 | NEELS GUIDO J Director | Purchase | 20,000 | $20.8K |
| Jan 29, 2026 | NEELS GUIDO J Director | Purchase | 15,000 | $15.9K |
| Jan 28, 2026 | NEELS GUIDO J Director | Purchase | 15,000 | $15.9K |
| Dec 17, 2025 | RAKIN KEVIN Director | Purchase | 50,000 | $26.0K |
| Dec 17, 2025 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Purchase | 60,000 | $31.8K |
| Dec 17, 2025 | Mills C Randal PRESIDENT AND CEO | Purchase | 3,000 | $1.5K |
| Dec 17, 2025 | Makes Brigid Director | Purchase | 25,000 | $13.0K |
| Dec 17, 2025 | Colpman David Director | Purchase | 12,500 | $6.4K |
| Dec 11, 2025 | RAKIN KEVIN Director | Other | 4,505,941 | — |
| Dec 10, 2025 | NEELS GUIDO J Director | Option exercise | 6,250 | — |
| Dec 10, 2025 | Mills C Randal PRESIDENT AND CEO | Tax withheld | 9,664 | $6.8K |
| Dec 10, 2025 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Option exercise | 12,500 | — |
| Dec 10, 2025 | Mills C Randal PRESIDENT AND CEO | Option exercise | 27,083 | — |
| Dec 10, 2025 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Tax withheld | 4,461 | $3.1K |
| Dec 10, 2025 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Option exercise | 12,500 | — |
| Dec 10, 2025 | Williams Michelle LeRoux CHIEF SCIENTIFIC OFFICER | Tax withheld | 3,951 | $2.8K |
| Dec 2, 2025 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Purchase | 5,500 | $3.7K |
| Dec 1, 2025 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Purchase | 4,500 | $2.9K |
| Dec 1, 2025 | NEELS GUIDO J Director | Option exercise | 6,250 | — |
| Nov 24, 2025 | Mills C Randal PRESIDENT AND CEO | Purchase | 5,000 | $3.0K |
| Nov 17, 2025 | Colpman David Director | Purchase | 15,500 | $11.5K |
| Nov 13, 2025 | Mills C Randal PRESIDENT AND CEO | Purchase | 5,000 | $3.7K |
| Nov 13, 2025 | Mills C Randal PRESIDENT AND CEO | Purchase | 3,500 | $2.7K |
| Nov 13, 2025 | Mills C Randal PRESIDENT AND CEO | Purchase | 5,000 | $3.8K |
| Sep 10, 2025 | Mills C Randal PRESIDENT AND CEO | Option exercise | 27,083 | — |
| Sep 10, 2025 | Mills C Randal PRESIDENT AND CEO | Tax withheld | 9,664 | $13.1K |
| Sep 10, 2025 | Ferguson Matthew CHIEF FINANCIAL OFFICER | Option exercise | 29,000 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ELUTIA INC.
Free account. Everything above stays public.
Write why you follow ELUTIA INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading